PubRank

Scott S Zamvil

Author PubWeight™ 73.52‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002 5.24
2 Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat Med 2007 3.09
3 Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 2006 2.70
4 How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann Neurol 2006 2.38
5 B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity. Ann Neurol 2010 2.17
6 MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies. J Exp Med 2013 1.88
7 Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. Arch Neurol 2008 1.88
8 Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter. Ann Neurol 2012 1.75
9 Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J Exp Med 2006 1.69
10 Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis. Trends Immunol 2005 1.63
11 Proinflammatory role of aquaporin-4 in autoimmune neuroinflammation. FASEB J 2011 1.50
12 B cells in multiple sclerosis: connecting the dots. Curr Opin Immunol 2011 1.45
13 Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. J Clin Invest 2006 1.43
14 Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity. PLoS One 2012 1.39
15 Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis. Proc Natl Acad Sci U S A 2009 1.31
16 Disease-modifying agents for multiple sclerosis: recent advances and future prospects. Drugs 2008 1.25
17 Depletion of B lymphocytes from cerebral perivascular spaces by rituximab. Arch Neurol 2009 1.24
18 Therapeutic decisions in multiple sclerosis: moving beyond efficacy. JAMA Neurol 2013 1.16
19 Statins as potential therapeutic agents in neuroinflammatory disorders. Curr Opin Neurol 2003 1.16
20 Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action. CNS Drugs 2011 1.15
21 The role of the MHC class II transactivator in class II expression and antigen presentation by astrocytes and in susceptibility to central nervous system autoimmune disease. J Immunol 2002 1.14
22 Immunodominant T cell determinants of aquaporin-4, the autoantigen associated with neuromyelitis optica. PLoS One 2010 1.13
23 Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? Arch Neurol 2010 1.11
24 Lymph node-derived donor encephalitogenic CD4+ T cells in C57BL/6 mice adoptive transfer experimental autoimmune encephalomyelitis highly express GM-CSF and T-bet. J Neuroinflammation 2011 1.11
25 Cholesterol-lowering statins possess anti-inflammatory activity that might be useful for treatment of MS. Neurology 2002 1.06
26 Switching multiple sclerosis patients with breakthrough disease to second-line therapy. PLoS One 2011 1.02
27 Mechanism of action of glatiramer acetate in treatment of multiple sclerosis. Neurotherapeutics 2007 1.01
28 Laquinimod, a once-daily oral drug in development for the treatment of relapsing-remitting multiple sclerosis. Expert Rev Clin Pharmacol 2012 0.99
29 B-cell very late antigen-4 deficiency reduces leukocyte recruitment and susceptibility to central nervous system autoimmunity. Ann Neurol 2015 0.98
30 Cutting edge: oral type I IFN-tau promotes a Th2 bias and enhances suppression of autoimmune encephalomyelitis by oral glatiramer acetate. J Immunol 2002 0.98
31 Simvastatin regulates oligodendroglial process dynamics and survival. Glia 2007 0.97
32 Repetitive pertussis toxin promotes development of regulatory T cells and prevents central nervous system autoimmune disease. PLoS One 2010 0.93
33 Tob1 plays a critical role in the activation of encephalitogenic T cells in CNS autoimmunity. J Exp Med 2013 0.93
34 Are statins a treatment option for multiple sclerosis? Lancet Neurol 2004 0.92
35 Statins in the treatment of central nervous system autoimmune disease. J Neuroimmunol 2006 0.91
36 Bench to bedside: tempering antigen-presenting cells in multiple sclerosis. Nat Med 2008 0.89
37 The immunogenicity of disease-modifying therapies for multiple sclerosis: clinical implications for neurologists. Neurologist 2007 0.89
38 A neuropeptide in immune-mediated inflammation, Y? Trends Immunol 2006 0.88
39 Precision medicine in chronic disease management: The multiple sclerosis BioScreen. Ann Neurol 2014 0.87
40 Beginning of the end of two-stage theory purporting that inflammation then degeneration explains pathogenesis of progressive multiple sclerosis. Curr Opin Neurol 2016 0.84
41 Drug Insight: using statins to treat neuroinflammatory disease. Nat Clin Pract Neurol 2005 0.84
42 Pharmacological treatment of early multiple sclerosis. Drugs 2008 0.84
43 Combination therapies for multiple sclerosis: scientific rationale, clinical trials, and clinical practice. Curr Opin Neurol 2007 0.83
44 The neonatal CNS is not conducive for encephalitogenic Th1 T cells and B cells during experimental autoimmune encephalomyelitis. J Neuroinflammation 2013 0.82
45 Combining statins with interferon β in multiple sclerosis: think twice, it might not be all right. Lancet Neurol 2011 0.82
46 Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis. Neurology 2004 0.82
47 Glatiramer acetate treatment does not modify the clinical course of (NZB x BXSB)F1 lupus murine model. Int Immunol 2008 0.81
48 Statins and their potential targets in multiple sclerosis therapy. Expert Opin Ther Targets 2003 0.81
49 T effectors outfox T regulators in autoimmunity. Nat Med 2007 0.80
50 Update on the autoimmune pathology of multiple sclerosis: B-cells as disease-drivers and therapeutic targets. Eur Neurol 2015 0.80
51 Accelerated central nervous system autoimmunity in BAFF-receptor-deficient mice. J Neurol Sci 2011 0.80
52 K+ channel alterations in the progression of experimental autoimmune encephalomyelitis. Neurobiol Dis 2012 0.80
53 Developmental maturation of innate immune cell function correlates with susceptibility to central nervous system autoimmunity. Eur J Immunol 2013 0.80
54 Translational research in neurology and neuroscience 2010: multiple sclerosis. Arch Neurol 2010 0.79
55 Re-engineering of pathogenic aquaporin 4-specific antibodies as molecular decoys to treat neuromyelitis optica. Ann Neurol 2012 0.79
56 Statins--treatment option for central nervous system autoimmune disease? Neurotherapeutics 2007 0.78
57 Neuroimmunotherapeutics comes of age. Neurotherapeutics 2007 0.78
58 Evaluation of HMG-CoA reductase inhibitors for multiple sclerosis: opportunities and obstacles. CNS Drugs 2005 0.78
59 Efficient technique for immortalization of murine microglial cells relevant for studies in murine models of multiple sclerosis. J Neurosci Methods 2003 0.77
60 FTY720 and central memory: out of sight, out of mind. Neurology 2010 0.75
61 Mitoxantrone as a potential therapy for primary progressive multiple sclerosis. Mult Scler 2004 0.75
62 Delivery of myelin peptides through the first line of defense, skin, to counter autoimmunity in multiple sclerosis. Ann Neurol 2010 0.75
63 Erratum: The ubiquitin-modifying enzyme A20 restricts ubiquitination of the kinase RIPK3 and protects cells from necroptosis. Nat Immunol 2015 0.75
64 Statins as potential therapeutic agents in multiple sclerosis. Curr Neurol Neurosci Rep 2004 0.75
65 Approved and future pharmacotherapy for multiple sclerosis. Neurologist 2002 0.75